Asahi Kasei Consolidates Pharmaceutical Units Under Single Brand
Tokyo-based Asahi Kasei is merging its global pharmaceutical units under a single brand, Asahi Kasei Therapeutics. This move comes after years of deal-driven expansion, including acquisitions in the US, Sweden, and Germany.
The company has been rapidly expanding through strategic deals since 2020. It acquired Veloxis Pharmaceuticals in 2020, Calliditas in 2024 for $1 billion, and most recently agreed to buy Aicuris for about $920 million in February this year.
Asahi Kasei Therapeutics will oversee the global management of its pharmaceutical business. The company's new structure allows for unified resource allocation decisions across the business, according to Yoshikazu Aoki, global president of Asahi Kasei Therapeutics. This integration also provides a stronger platform for in-licensing opportunities.
The conglomerate is targeting $2 billion in sales by the end of the decade and plans to invest about 40 billion Japanese yen ($250 million) in in-licensing over the next three years.